Neurobiology of Nutrition Laboratory
News & Announcements
- Dr. Shin's research is featured on the Diabetes Action Foundation research page for his current study aiming to identify and test the role of specific neuronal populations within the MBH for BCAA regulation. https://diabetesaction.org/current-research
- Ritchel B. Gannaban is the first author of our research findings now published in Diabetes, "Central regulation of branched-chain amino acids is mediated by AgRP neurons". Congratulations!
- Dr. Ganga Baskar, a previous postdoctoral fellow in the lab, is appointed as the Commercialization Program Director in the Innovation Hub at TTU. Congratulations!
- Harsh Shah was highlighted in the COHS News (9/4/20): https://www.depts.ttu.edu/hs/news/posts/2020/student/ns-graduate-student-testimonial-research-opportunities-harsh-shah.php
- Ritchel B. Gannaban was selected as a Helen Hodges Scholar from Helen Hodges Educational Charitable Trust. Congratulations!
- Dr. Andrew Shin secured a grant from the Diabetes Action Foundation, "Understanding BCAA regulation – a step toward deciphering diabetes".
- Caitlyn Mullins is the first author of our review paper in Antioxidants, "Neural Underpinnings of Obesity: The Role of Oxidative Stress and Inflammation in the Brain". Congratulations!
We are interested in how the brain is able to integrate nutrient-related signals from various tissues in the body to control body weight and appetite, as well as nutrient metabolism (glucose, amino acids, lipids) in the context of obesity and diabetes. Related to this, we also study how Roux-en-Y gastric bypass (RYGB), a type of bariatric surgery considered to be one of the most effective treatments for obesity/diabetes, successfully lowers body weight and improves metabolic outcomes. How RYGB surgery rewires both "homeostatic" and "hedonic/reward" systems to defend the new lower body weight is a very interesting topic. We are also interested in parsing out the relationship between diabetes and Alzheimer's disease (AD), and in identifying novel biomarkers and treatments for AD.